Basilea Pharmaceutica AG Allschwil
SWB:PK5
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
32.6
63
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PK5 stock under the Base Case scenario is hidden EUR. Compared to the current market price of 57.4 EUR, Basilea Pharmaceutica AG Allschwil is hidden .
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Basilea Pharmaceutica AG Allschwil
PK5 looks overvalued. Yet it might still be cheap by its own standards. Some stocks live permanently above intrinsic value; Historical Valuation reveals whether PK5 usually does or if today's premium is unusual.
Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Basilea Pharmaceutica AG Allschwil.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Revenue & Expenses Breakdown
Basilea Pharmaceutica AG Allschwil
Balance Sheet Decomposition
Basilea Pharmaceutica AG Allschwil
| Current Assets | 217.5m |
| Cash & Short-Term Investments | 128.4m |
| Receivables | 57.3m |
| Other Current Assets | 31.8m |
| Non-Current Assets | 31.4m |
| PP&E | 17.5m |
| Intangibles | 335k |
| Other Non-Current Assets | 13.5m |
| Current Liabilities | 34.4m |
| Accounts Payable | 9.9m |
| Accrued Liabilities | 19.4m |
| Other Current Liabilities | 5.1m |
| Non-Current Liabilities | 111.3m |
| Long-Term Debt | 82m |
| Other Non-Current Liabilities | 29.3m |
Free Cash Flow Analysis
Basilea Pharmaceutica AG Allschwil
| CHF | |
| Free Cash Flow | CHF |
Earnings Waterfall
Basilea Pharmaceutica AG Allschwil
|
Revenue
|
236.2m
CHF
|
|
Cost of Revenue
|
-44.8m
CHF
|
|
Gross Profit
|
191.4m
CHF
|
|
Operating Expenses
|
-115.5m
CHF
|
|
Operating Income
|
76m
CHF
|
|
Other Expenses
|
-3.3m
CHF
|
|
Net Income
|
72.7m
CHF
|
PK5 Profitability Score
Profitability Due Diligence
Basilea Pharmaceutica AG Allschwil's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Basilea Pharmaceutica AG Allschwil's profitability score is hidden . The higher the profitability score, the more profitable the company is.
PK5 Solvency Score
Solvency Due Diligence
Basilea Pharmaceutica AG Allschwil's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Basilea Pharmaceutica AG Allschwil's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PK5 Price Targets Summary
Basilea Pharmaceutica AG Allschwil
Dividends
Current shareholder yield for PK5 is hidden .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one PK5 stock under the Base Case scenario is hidden EUR.
Compared to the current market price of 57.4 EUR, Basilea Pharmaceutica AG Allschwil is hidden .